8-K - Atea Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Management Change+4 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

is incorporated by reference herein. On April 16, 2025, the Board appointed Howard H. Berman, Ph.D. as a Class III director of the Company, effective at the Eff

Material Agreement

$45.0K

Source Document

2.02

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”

Financial Results

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The informati

Management Change

7.01

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits. 10.1 Letter Agreement, by and between Atea Pharmaceuticals, Inc., Bradley L. Radoff, JEC II Associates, LLC and

Exhibits Only

Source Document

Exhibits (3)

10.1

EX-10.1

8-K

99.1

EX-99.1